Cadrenal Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own64.16% Shs Outstand11.63M Perf Week-21.58%
Market Cap26.18M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.60M Perf Month-
Income- PEG- EPS next Q- Inst Own- Short Float / Ratio- / - Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Interest- Perf Half Y-
Book/sh-0.14 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.15 - 6.75 Perf YTD-47.09%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.70% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low1.40% ATR0.70
Employees1 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility12.87% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.07 Prev Close2.25
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.08M Price2.18
Recom- SMA20-25.26% SMA50-25.26% SMA200-25.26% Volume48,286 Change-3.11%
Feb-06-23 09:00AM
Feb-01-23 09:00AM
Jan-24-23 02:11PM
Jan-23-23 11:39AM
09:31AM Loading…
Jan-20-23 09:31AM
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.